Literature DB >> 31701359

Identifying optimal heparin management during cardiopulmonary bypass in Chinese people: a retrospective observational comparative study.

Yongbo Gan1, Zhijian Yang1, Wei Mei2, Chang Zhu3.   

Abstract

Traditionally heparin is adapted according to total body weight (TBW) to providing anticoagulation during cardiopulmonary bypass (CPB), but it may be inaccurate in some patients. The medical records of 100 adult patients who received CPB in Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology over a 10-month period in 2017 were included in the retrospective study. An unfractionated heparin (UFH) bolus of 300 IU/kg TBW was injected before initiation of CPB followed by additional doses (50 to 100 IU/kg) to maintain a target activated coagulation time (ACT) of at least 480 s. We used TBW, ideal body weight (IBW), lean body weight (LBW), or body mass index (BMI) to establish and evaluate a linear model of ACT and the amount of heparin respectively. The linear fit effect of the model based on BMI on the original data is better than the others. As the instruments to measure heparin concentration is unavailable in most medical institutions in China. The new linear model based on BMI is helpful to estimate a more individualized heparin dosage in the heparinized phase and to provide useful reference to the amount of remaining heparin in the neutralization phase.

Entities:  

Keywords:  Anticoagulants; Body mass index; Cardiopulmonary bypass; Heparin

Mesh:

Substances:

Year:  2020        PMID: 31701359     DOI: 10.1007/s11239-019-01987-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

1.  Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?

Authors:  Mya S Baker; Julian R Skoyles; Frca Matt Shajar; Henry Skinner; David Richens; Ian M Mitchell
Journal:  J Extra Corpor Technol       Date:  2005-06

2.  An Adjusted Calculation Model of Reduced Heparin Doses in Cardiopulmonary Bypass Surgery in a Chinese Population.

Authors:  Yufeng Zhang; Kai Liu; Wei Li; Qian Xue; Jiang Hong; Jibin Xu; Lihui Wu; Guangyu Ji; Jihong Sheng; Zhinong Wang
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-04-12       Impact factor: 2.628

Review 3.  Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review.

Authors:  C Boer; M I Meesters; D Veerhoek; A B A Vonk
Journal:  Br J Anaesth       Date:  2018-02-26       Impact factor: 9.166

Review 4.  The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor A Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John W Hammon
Journal:  Ann Thorac Surg       Date:  2018-01-19       Impact factor: 4.330

5.  Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients: A randomised controlled trial.

Authors:  Matthias Vienne; Emmanuel Haas; Thibaut Wipf; Lelia Grunebaum; François Levy; Laurent Sattler; Tam Hoang Minh; François Severac; Charles Tacquard; Olivier Collange; Paul-Michel Mertes; Annick Steib
Journal:  Eur J Anaesthesiol       Date:  2018-08       Impact factor: 4.330

6.  Obesity and clotting: Body mass index independently contributes to hypercoagulability after injury.

Authors:  Lucy Z Kornblith; Benjamin Howard; Ryan Kunitake; Brittney Redick; Mary Nelson; Mitchell Jay Cohen; Rachael Callcut
Journal:  J Trauma Acute Care Surg       Date:  2015-01       Impact factor: 3.313

7.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

Authors:  B S Bull; W M Huse; F S Brauer; R A Korpman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

8.  Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time.

Authors:  P D Raymond; M J Ray; S N Callen; N A Marsh
Journal:  Perfusion       Date:  2003-09       Impact factor: 1.972

9.  Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery.

Authors:  Zaishen Jia; Ganzhong Tian; Yupeng Ren; Zhiquan Sun; Wei Lu; Xiaotong Hou
Journal:  J Transl Med       Date:  2015-02-01       Impact factor: 5.531

10.  Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass.

Authors:  X Delavenne; E Ollier; S Chollet; F Sandri; J Lanoiselée; S Hodin; A Montmartin; J-F Fuzellier; P Mismetti; L Gergelé
Journal:  Br J Anaesth       Date:  2017-05-01       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.